The gene chips have been extensively studies and widely applied.Gene chip technology provides a powerful tool for molecular nutrition.This article reviews the rationales,classification,characteristics of gene chips,and their application in molecular nutrition.

OBJECTIVE:To investigate the improvement effect of Prostatitis capsule on chronic non-bacterial prostatitis(CNP) model rats. METHODS:60 rats were randomly divided into sham operation group (distilled water),model group (distilled wa-ter),Pule'an tablet group(positive control,2 g/kg)and Prostatitis capsule high-dose,medium-dose,low-dose groups(16,8,4 g/kg). Except for sham operation group,other 5 groups were injected Xiaozhiling injection 0.2 mL to reduce CNP model. After 7 d of modeling,they received related medicines,ig,once a day,for 45 d. After 24 h of last administration,prostate lesions were ob-served by eyes and wet quality was weighed. White blood cell(WBC)count and lecithin body(SPL)count were conducted under microscope,and prostate tissue slices were pathologically observed. RESULTS:Compared with sham operation group,prostate showed gray nodules,adhesion in glands and surrounding tissue;wet quality of prostate and WBC,SPL count in prostate tissue were significantly increased(P<0.01);under microscope,there were significant congestion,edema and a variety of inflammatory cell infiltration in prostate interstitial. Compared with model group,gray nodules in prostate in Pule'an tablet group and Prostatitis capsule group were reduced,as well as adhesion degree in prostate and surrounding tissue;wet quality of prostate and WBC,SPL count in prostate tissue were significantly decreased(P<0.01);pathological changes had improved to varying degrees under micro-scope,especially the changes in Prostatitis capsule high-dose group,and prostate tissue only showed mild congestion,edema and little inflammatory cell infiltration. CONCLUSIONS:Prostatitis capsule has a certain improvement effect on CNP model rats.

Objective To analyze the survey results of iodine nutritional level among women of childbearing age,pregnant,lactating women and infants before and after the adjustment of iodine concentration in salt of Zibo City,in order to provide a scientific basis for reasonable iodine supplement.Methods The iodine content in the residents' edible salt samples was determined in 2011 and 2015.Four groups of target populations including women of childbearing age,pregnant,lactating women and infants from 7 districts and towns of Zibo were investigated to test their urinary iodine level in 2011 and 2015.The monitoring results of the two years were compared and analyzed.Results A total of 2 100 and 2 160 residents edible salt were monitored in 2011 and 2015,and the median of salt iodine were 30.2 and 22.7 mg/kg,there was statistically significant difference in the constitute of salt iodine level between the two years (x2 =141.90,P ＜ 0.01).A total of 354,402,403,362 urine samples of women of childbearing age,pregnant,lactating women and infants' were detected and the median urinary iodine were 161.80,127.20,138.80,147.10 μg/L in 2011,and 350,706,350 and 352 of the corresponding target population's urine samples were detected and the median urinary iodine were 127.80,129.95,70.20 and 152.35 μg/L in 2015.Conclusions The salt iodine median has reduced and the urinary iodine in childbearing age women and infant is in the appropriate level,while it is insufficient in the pregnant women and lactating women after the adjustment of iodized salt concentration in Zibo.It is necessary to promote health education and instruct pregnant women and lactating women to supplement iodine,additionally,surveillance of the iodine nutrition status of the targeted populations should be strengthened.

Objective To observe the efficacy of autologous hematopoietic stem cell transplantation (auto-AHSCT) in treatment of malignant hemopathy. Methods A retrospective study was accomplished on the auto-AHSCT in the treatment of 28 patients with malignant hemopathy from Oct 1994 to May 2009. The median age of the patients was 30 (16-45) years. Among the 28 patients,19 cases were acute myelocytic leukemia (AML),4 cases were acute lymphoblastic leukemia (ALL) and 5 cases were malignant lymphoma (ML). Mobilization of peripheral blood stem cell was recieved by giving granulocyte colony-stimulating factor (G-CSF) 5-10 μg/kg. The patients were pretreated with melphalan (140-160 mg/m2),cyclophosphamide (120 mg/kg) and arabinosylcytosin (2 g/m2). Results Transplant-related side effects was less and the hematologic recovery of most patients(26 cases) was quite rapid. The days to stable neutrophil count of 0.5×109/L and platelet count of 20×109/L were 12(8-38) d and 14(9-128) d,respectively. The median followup duration was 36(7-68) months. 19 cases (68 %) achieved disease-free survival(DFS) and 9 cases (32 %)died in three years. Of the 9 death patients,7 cases (25 %) died of recurrence and 2 cases (7 %) died of posttransplant complications. Conclusion AHSCT is a safe and effective therapy method for malignant hemopathy.

Objective:To investigate COVID-19 vaccination status and relevant adverse reactions in patients with psoriasis treated with biological agents, and to explore the effect of COVID-19 vaccination on psoriatic lesions.Methods:Clinical data were collected from 572 psoriasis patients aged 18 - 60 years, who were registered in the management system of psoriasis patients treated with biological agents in the University of Hong Kong-Shenzhen Hospital from May 2019 to June 2021. The COVID-19 vaccination status was investigated by telephone interviews, and the vaccination-related information was obtained by fixed healthcare workers during a fixed time period according to a predesigned questionnaire. Measurement data were compared between two groups by using t test, and enumeration data were compared by using chi-square test or Fisher′s exact test. Results:The COVID-19 vaccination coverage rate was 43.13% (226 cases) among the 524 patients who completed the telephone interview, and was significantly lower in the biological agent treatment group (30.79%, 105/341) than in the traditional drug treatment group (66.12%, 121/183; χ2 = 60.60, P < 0.001) . The main reason for not being vaccinated was patients′ fear of vaccine safety (49.66%, 148/298) , followed by doctors′ not recommending (26.51%, 79/298) . In the biological agent treatment group after vaccination, the exacerbation of psoriatic lesions was more common in patients receiving prolonged-interval treatment (42.86%, 6/14) compared with those receiving regular treatment (4.40%, 4/91; Fisher′s exact test, P < 0.001) . Skin lesions were severely aggravated in two patients after COVID-19 vaccination, who ever experienced allergic reactions and whose skin lesions did not completely subside after the treatment with biological agents. Conclusions:The COVID-19 vaccination coverage rate was relatively low in the psoriasis patients treated with biological agents, and no serious adverse reaction was observed after vaccination. Prolonged-interval treatment due to COVID-19 vaccination ran the risk of exacerbation of skin lesions.